Washington talks endlessly about strengthening America’s healthcare system. The real test is whether policymakers are willing to fix the weak links in the pharmaceutical supply chain that patients depend on every day.
The Trump administration has made patient access a priority, issuing executive orders aimed at lowering costs and improving the reliability of drug supply. But if policymakers want to make the system more resilient, they should start with a simple fix: allow regulated pharmaceutical outsourcing facilities to do the job they were created to do.
America’s pharmaceutical supply chain has been operating on thin margins for years. There is little redundancy and even less capacity to absorb disruption. When manufacturing delays hit or demand surges, the system buckles quickly. Patients and providers are left scrambling for alternatives, and too often there aren’t any.
One underutilized solution already exists inside the regulatory framework: 503B pharmaceutical outsourcing facilities.
To understand their importance, it helps to understand the distinction within the compounding system. Traditional 503A compounding pharmacies prepare medications for individual patients and are primarily regulated by the states. 503B outsourcing facilities, by contrast, are FDA-regulated manufacturing operations capable of producing sterile compounded medications at scale for hospitals, clinics, and pharmacies. They operate under strict federal manufacturing standards and oversight.
Yet despite operating under tougher regulations, 503B facilities are paradoxically allowed to produce fewer products than 503A pharmacies. That mismatch makes little sense. Facilities with higher regulatory scrutiny should not face tighter production limits than those operating under lighter oversight.
The result is a regulatory bottleneck that weakens the supply chain instead of strengthening it.
Congress created 503B outsourcing facilities to serve as a regulated pressure-release valve in the pharmaceutical system. When drug shortages emerge or supply disruptions occur, these facilities should be able to step in with scalable production. Instead, current policy limits their ability to do exactly that.
A straightforward policy reform would align the production authority of 503B facilities with the products already compounded by 503A pharmacies. Doing so would expand domestic manufacturing capacity, reduce regulatory friction, and strengthen the resilience of the drug supply chain.
The stakes are not theoretical. Patients who rely on continuous treatment feel the consequences immediately when access disappears.
Consider GLP-1 therapies such as semaglutide and tirzepatide. Millions of Americans managing obesity, insulin resistance, or Type 2 diabetes depend on these medications. Interruptions in treatment can lead to weight rebound, worsening blood sugar control, and increased cardiovascular risk. When legitimate supply disappears, patients are pushed into gray markets, online sellers, or even foreign suppliers—where safety and quality cannot be guaranteed.
503B outsourcing facilities exist precisely to prevent that outcome. They keep production inside the regulated U.S. system and ensure patients have access to safe, reliable medications when supply disruptions occur.
This is not a complicated policy challenge. The production capacity already exists. The regulatory structure already exists. What’s missing is the political will to align policy with reality.
Encouragingly, more lawmakers are beginning to recognize that outsourcing facilities are a critical component of America’s healthcare infrastructure. If Washington is serious about supply-chain resilience and patient access, it should empower these facilities to operate at their full potential.
Sometimes strengthening the healthcare system doesn’t require inventing something new. It simply requires letting the right players get on the field.
At a moment when Washington is debating drug pricing, domestic manufacturing, and how to reduce America’s dependence on fragile global supply chains, empowering 503B outsourcing facilities should be an obvious bipartisan step. If the Trump administration is serious about putting American patients first—and about bringing more pharmaceutical production back home—then regulatory policy must match that ambition. The capacity already exists inside the United States. What’s needed now is the willingness to remove outdated barriers and allow 503B facilities to strengthen the supply chain, expand access, and ensure that when Americans need their medications, the system delivers.
